Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency

Am J Cardiol. 2002 May 15;89(10):1209-11. doi: 10.1016/s0002-9149(02)02308-1.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Abciximab
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Anticoagulants / therapeutic use*
  • Cardiac Surgical Procedures*
  • Coronary Artery Disease / complications*
  • Coronary Artery Disease / mortality
  • Coronary Artery Disease / surgery*
  • Drug Evaluation
  • Female
  • Follow-Up Studies
  • Hemoglobins / analysis
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use*
  • Incidence
  • Kidney Failure, Chronic / complications*
  • Kidney Failure, Chronic / drug therapy*
  • Kidney Failure, Chronic / mortality
  • Male
  • Middle Aged
  • Ohio / epidemiology
  • Platelet Glycoprotein GPIIb-IIIa Complex / therapeutic use
  • Postoperative Hemorrhage / etiology
  • Risk Factors
  • Thrombocytopenia / etiology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Anticoagulants
  • Hemoglobins
  • Immunoglobulin Fab Fragments
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Abciximab